IL-6, His, Mouse Protein
- Known as:
- Interleukin-6, histidine, Mouse Protein
- Catalog number:
- z03189-25
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Genscript
- Gene target:
- IL-6 His Mouse Protein
Related genes to: IL-6, His, Mouse Protein
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: IL-6, His, Mouse Protein
Related articles to: IL-6, His, Mouse Protein
- Multifunctional theranostic nanoplatforms enabling precise targeting and controlled deep tissue therapy are vital. Herein, we present a self-assembled, defect-engineered, biomimetic nanoplatform (CDMBBTO), in which piezoelectric material and downconversion nanoparticles (DCNPs) are co-assembled within a polymer matrix, preventing interactions between both components, thereby allowing each to retain its intrinsic properties while collectively enabling dual second near infrared fluorescence (NIR-II FL)/magnetic resonance (MR) imaging and synergistic piezo/chemodynamic therapy (PZDT/CDT). Mn/Bi codoped piezoelectric BaTiO (MBBTO) NPs exhibit a significantly enhanced piezoelectric coefficient (~5 fold higher than pristine BTO) owing to bandgap modulation induced by defect engineering. The incorporated Mn not only catalyzes Fenton like reactions for sustained tumor suppression but also provides strong T weighted MR contrast. Self-assembled NIR-II emissive DCNPs enable deep tissue optical imaging, forming an integrated theranostic system. Cloaking of U87 glioma cell membranes imparts homologous tumor targeting capability. In vivo dual modal imaging reveals efficient tumor accumulation, with peak NIR-II FL and MR signal intensities observed 6 h post-injection. Upon ultrasound activation, CDMBBTO elicits potent tumor ablation through synergistic reactive oxygen species generation and immune modulation, characterized by macrophage polarization (M2 → M1) and upregulation of proinflammatory cytokines (TNF-α and IL-6). This work establishes CDMBBTO as a powerful nanoplatform for dual modal imaging-guided, immune potentiated PZDT/CDT toward effective glioblastoma treatment. - Source: PubMed
Publication date: 2026/06/26
Hasan IkramUllah ZiaWang FeiWang LiYan YibinGong TingtingMadni MuhammadMondal DhananjoyQu HanyangRoy JhilikZhang YingheRoy ShubhamGuo BingChang Chunqi - Vestibular migraine (VM) is characterized by recurrent episodes of headache and vertigo, and its pathogenesis is closely associated with neuroinflammation and central sensitization. C-X-C motif chemokine ligand 10 (CXCL10) plays a critical role in neuroinflammation and pain modulation; however, its specific involvement in VM remains unclear. - Source: PubMed
Publication date: 2026/06/26
Song Mao-MeiCoppola GianlucaGao Ying-JieSong Shi-NaLi Chang-XinXu Sui-Yi - Among HER2-positive breast cancer patients, those who do not achieve pathological complete response (non-pCR) after neoadjuvant chemotherapy (NAC) generally have poorer outcomes. Although additional postoperative therapies have been developed, it remains unclear which patients truly require treatment intensification. This study aimed to identify prognostic factors in non-pCR patients. - Source: PubMed
Publication date: 2026/06/27
Ueki YukoHorimoto YoshiyaYuan MenWu RongrongUshiyama YumikoIshizuka YumikoOnagi HirokoHayashi TakuoKawate TakahikoIshikawa TakashiWatanabe JunichiroKutomi Goro - Sepsis-associated acute kidney injury (SA-AKI) is a common and severe complication in critically ill patients with high mortality, characterized by a dysregulated inflammatory response and oxidative stress. Chrysophanol (CHR), a natural anthraquinone, has demonstrated anti-inflammatory properties in other septic conditions, but its role and mechanism in SA-AKI remain unclear. This study aimed to investigate the protective effects of CHR against SA-AKI and the underlying mechanisms. Cell viability, inflammatory cytokine expression (IL-6, IL-1β, TNF-α, MCP-1, IL-10), and intracellular reactive oxygen species (ROS) levels were assessed after CHR pretreatment. An in vivo model was established using LPS method. Renal injury was evaluated through histopathology (H&E, Masson's, TUNEL staining), renal function (serum creatinine and BUN), and systemic inflammation (serum IL-6, TNF-α, IL-10). In vitro, LPS significantly reduced HK-2 cell viability and increased the production of pro-inflammatory cytokines and ROS. CHR pretreatment restored cell viability, suppressed the mRNA levels of IL-6, IL-1β, TNF-α, and MCP-1, enhanced IL-10 expression, and reduced intracellular ROS levels. In vivo, LPS-induced mice exhibited severe renal pathological damage, apoptosis, collagen deposition, and elevated serum creatinine and BUN. CHR treatment attenuate these pathological changes, reduced renal injury scores and apoptosis, and improved renal function. Furthermore, CHR significantly decreased serum levels of pro-inflammatory IL-6 and TNF-α while increasing the anti-inflammatory cytokine IL-10 in LPS mice. Chrysophanol treatment is associated with improved cell survival, reduced inflammatory cytokine expression, and decreased oxidative stress in LPS-stimulated HK-2 cells and septic mice. These associations suggest a potential protective role of chrysophanol in SA-AKI, though the underlying molecular mechanisms require further investigation. - Source: PubMed
Publication date: 2026/06/27
Li XiaoxiaoOuyang BingqingZhang MengdiSun HaoranYe HuiYou LijiaoYuan WeifangWang HaikuoYang HainanXu KailangLei Ming - Candida auris (C. auris) is an emerging fungal pathogen with a remarkable ability to persist on human skin, but how structural skin cells respond to colonization is unclear. We used ex vivo human skin models, together with primary keratinocytes and fibroblasts, to characterize epithelial and stromal responses to C. auris compared with Candida albicans. C. auris formed biofilms and induced a wound-model-dependent pattern of cytokine secretion dominated by IL-1β and IL-6, yet caused minimal epithelial damage and modest reductions in leukocyte viability. RNA sequencing revealed complementary but cell-type-specific responses. Keratinocytes and fibroblasts both amplified a pro-inflammatory IL-6/CXCL8 response, while keratinocytes additionally upregulated antimicrobial genes such as RNASE7, TSLP, DEFB103A (encoding hBD-3), and the neutrophil-recruiting chemokines CXCL2 and CXCL3. Fibroblasts further induced CCL28, supporting T cell recruitment, alongside transcriptional programs associated with tissue remodeling. Recombinant RNase 7 and short form TSLP directly inhibited C. auris growth in vitro in a dose-dependent manner. Together, these findings identify keratinocytes as epithelial sentinels that integrate inflammatory and antimicrobial defenses against skin-tropic C. auris and suggest that fibroblast-driven cytokine amplification and especially antimicrobial peptides from within the skin barrier may provide therapeutic targets to limit C. auris skin colonization. - Source: PubMed
Publication date: 2026/06/26
Seiser SaskiaBrezovec HelenaPenninger PhilippPhan-Canh TrinhMoser DorisAssen Frank PAyub TanyaRademacher FranziskaGläser RegineCerbu DianaKienzl PhilipFreystätter ChristianHarder JürgenKuchler KarlElbe-Bürger Adelheid